Navigation Links
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology

Rituxan Significantly Reduced Signs of Disease Activity as Measured by MRI and Relapse --

BOSTON -- May 1, 2007 -- Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that positive data from a Phase II clinical study of Rituxan® (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells.

"There remains a great need for safe and effective treatments for patients with RRMS,"said Stephen Hauser, MD, Professor and Chair, Department of Neurology, University of California, San Francisco. "These Phase II results are very encouraging and suggest B-cells play a key role in MS. They also lend support to the concept that selective targeting of B-cells may be an important approach to treating this debilitating disease."

In this Phase II double-blind, placebo-controlled study that evaluated the safety and efficacy of Rituxan in adult patients with RRMS, 104 patients were randomized to receive either a single treatment course of Rituxan (two infusions separated by two weeks) or placebo. The primary endpoint was defined as the total number of gadolinium-enhancing T1 lesions at weeks 12, 16, 20 and 24, as measured by serial MRI scans of the brain. The total number of gadolinium lesions at weeks 12, 16, 20 and 24 was statistically significantly reduced in patients receiving Rituxan compared to those receiving placebo (p<0.0001). At week 24, the total cumulative mean number of gadolinium lesions per patient was reduced by 91 percent, to 0.5 in the Rituxan-treated group from 5.5 in the placebo group.

In addition, the proportion of patients with relapses over 24 weeks in the Rituxan-treated arm was 14.5 percent compared to 34.3 percent in the
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural ... women for 19 years and found that, among those who had a stroke, people ... report is part of the September 2015 issue of “Natural Insights for Well Being,” ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The ... and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection ... same mission – to raise awareness of the FSH Society and further FSHD research. ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, ... being named a “Best of the Best” firm in the U.S., as well as ... “Best of the Best” in the U.S., selected exclusively on performance in specific areas ...
(Date:9/1/2015)... ... September 01, 2015 , ... Suzanne Bakken, PhD, ... at the Institute of Medicine (IOM) of the National Academies. , She is ... School of Nursing. A member of the Institute of Medicine since 2006, Bakken ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... performs and makes the massage robots more effective and humanlike than ever before. With ... massage chairs, the Ogawa Refresh and the Ogawa Active SuperTrac. , As in ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3
... with a history of growths in their colon may actually ... most colorectal cancer develop out of polyps, or adenomas, which ... the latest research, conducted in France, Denmark, Italy and Germany, ... in patients given this fibre supplementation. In 456 patients with ...
... researchers, a new treatment has been effective for inoperable liver cancer. It ... and it is showing a 25 ... per cent success rate in either reducing tumour size or the ... treatment with advanced liver tumours, who cannot be treated by any other ...
... dementia benefit from music therapy. The therapy involves professional musicians ... found that the therapy is popular with patients and can ... London are planning to carry out a study to see ... benefits for dementia sufferers. If their results are positive, the ...
... babies with low birth weight can significantly improve survival ... infectious diseases. The research involved 1,154 full-term but smaller ... weighing 5 1/2 pounds or less. Mothers fed them ... of the 20 who died had not been receiving ...
... Medicine Shoppe India (MSI), the sole franchisee for US based ... and Pune, has dropped Chennai from list of its target ... which recently drew up plans to expand its franchisee operations ... of the current financial year, has decided to put on ...
... day with a heavy breakfast and a steaming cup of tea ... who eat fried food each morning are at twice the ... best way to reduce the incidence of cancer is to begin ... ,Cancer of the oesophagus - the food pipe connecting ...
Cached Medicine News:Health News:Cut down on fries 2
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
...
Medicine Products: